ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   
 Top Breaking News
 Saturday, November 22, 2014

France Strikes Deal For Gilead Sciences, Inc. (GILD)'s Hep C Drug Sovaldi

AbbVie (ABBV) Nabs Positive CHMP Opinions For VIEKIRAX Plus EXVIERA To Treat HCV

Purdue Pharma L.P. Wins FDA Approval For Powerful Painkiller Hysingla

Genzyme Europe BV Cerdelga Gets EU Recommended For Approval In Type 1 Gaucher Disease

European Medicines Agency Recommends Availability Of Laboratoire HRA Pharma's Ellaone Emergency Contraceptive Without Prescription

Celgene (CELG) Receives Positive CHMP Opinion For OTEZLA (apremilast), The First Oral PDE4 Inhibitor For The Treatment Of Patients With Psoriasis And Psoriatic Arthritis

Regeneron (REGN), ReGen Therapeutics Plc (RGT.L) Eczema Drug Dupilumab Gets Sanofi (SAN.PA) Breakthrough Therapy Designation

Sanofi (SAN.PA) Aims To Launch 18 New Drugs By 2020

More News



 Yesterday's Most Popular News 
Top 10 Countries For Diabetes Clinical Research

Regeneron (REGN), ReGen Therapeutics Plc (RGT.L) Eczema Drug Dupilumab Gets Sanofi (SAN.PA) Breakthrough Therapy Designation

Sanofi (SAN.PA) Aims To Launch 18 New Drugs By 2020

A New Test Measures Analytical Thinking Linked To Depression, Fueling The Idea That Depression May Be A Form Of Adaptation, McMaster University Study

Sanofi (SAN.PA) And Regeneron (REGN)'s Alirocumab Ph3 Trials Met Primary Efficacy Endpoint

High Heels May Enhance A Man’s Instinct To Be Helpful, Université de Bretagne-Sud Study

Low Vitamin D Levels Increase Mortality, University of Copenhagen Study

National Institute for Clinical Excellence (NICE) Requests More Info On Novartis AG (NVS)'s Xolair To Treat Chronic Hives

University of California, Los Angeles (UCLA) Stem Cell Researcher Pioneers Gene Therapy Cure For Children With “Bubble Baby” Disease

PharmaEngine Announces The Receipt Of US FDA Fast Track Designation For MM-398 In Post-Gemcitabine Metastatic Pancreatic Cancer By Merrimack Pharmaceuticals Inc. (MACK)


 
-

 Featured Stories
 

  Today's Top Jobs

 Featured Employer
About Genzyme Genzyme is committed to discovering and delivering transformative therapies for patients with rare and special unmet medical needs, providing hope where there was none before. Genzyme has pioneered the development and delivery of transformative therapies for over 30 years. Founded in 1981 in Boston, Massachusetts, Genzyme evolved from a tiny start-up with just a handful of employees to one of the world's leading biotech companies. Acquired by Sanofi in 2011, Genzyme now benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Genzyme has long been known for our expertise in the class of rare genetic diseases known as lysosomal storage disorders (LSDs). LSDs remain the heart of our company today, but we have also expanded – through both in-house development and strategic acquisitions and partnerships – to other disease areas such as thyroid cancer and multiple sclerosis. Learn more at www.jobsatgenzyme.com. Follow our jobs on Twitter www.twitter.com/genzymejobs. Follow us on LinkedIn http://www.linkedin.com/company/genzyme. About Sanofi Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets, and animal health. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Show me jobs for this employer

 Careers
 
More Career Tips